RIPK1 ablation in T cells results in spontaneous enteropathy and TNF-driven villus atrophy
RIPK1 is a crucial regulator of cell survival, inflammation and cell death. Human RIPK1 deficiency leads to early-onset intestinal inflammation and peripheral T cell imbalance, though its role in αβT cell-mediated intestinal homeostasis remains unclear. In this study, we demonstrate that mice with RIPK1 ablation in conventional αβT cells (Ripk1<sup>ΔCD4</sup>) developed a severe small intestinal pathology characterized by small intestinal elongation, crypt hyperplasia, and duodenum-specific villus atrophy. Using mixed bone marrow chimeras reveals a survival disadvantage of αβT cells compared to γδT cells in the small intestine. Broad-spectrum antibiotic treatment ameliorates crypt hyperplasia and prevents intestinal elongation, though villus atrophy persists. Conversely, crossing Ripk1<sup>ΔCD4</sup> with TNF receptor 1 Tnfr1<sup>-/-</sup> knockout mice rescues villus atrophy but not intestinal elongation. Finally, combined ablation of Ripk1<sup>∆CD4</sup> and Casp8<sup>∆CD4</sup> fully rescues intestinal pathology, revealing that αβT cell apoptosis in Ripk1<sup>∆CD4</sup> drives the enteropathy. These findings demonstrate that RIPK1-mediated survival of αβT cells is essential for proximal small intestinal homeostasis. In Ripk1<sup>∆CD4</sup> mice, the imbalanced T cell compartment drives microbiome-mediated intestinal elongation and TNF-driven villus atrophy.
Authors
- A Brown (ORCID: https://orcid.org/0000-0002-1163-8283)
- Tatyana Divert
- Mario Pérez (ORCID: https://orcid.org/0000-0001-8345-5200)
- Marie Joossens (ORCID: https://orcid.org/0000-0001-8410-5528)
- Wim Declercq (ORCID: https://orcid.org/0000-0002-8218-2017)
- Bruno Verstraeten (ORCID: https://orcid.org/0000-0003-3573-1463)
- Nozomi Takahashi (ORCID: https://orcid.org/0000-0002-3751-4203)
- Jelle Huysentruyt (ORCID: https://orcid.org/0000-0001-8192-3031)
- Kelly Lemeire (ORCID: https://orcid.org/0000-0002-5319-6751)
- Bart N. Lambrecht (ORCID: https://orcid.org/0000-0003-4376-6834)
- Jonathan Maelfait (ORCID: https://orcid.org/0000-0002-1476-0583)
- Peter Tougaard (ORCID: https://orcid.org/0000-0003-1304-4152)
- Tom Vanden Berghe (ORCID: https://orcid.org/0000-0002-1633-0974)
- Peter Vandenabeele (ORCID: https://orcid.org/0000-0002-6669-8822)
- Wolf Steels (ORCID: https://orcid.org/0000-0001-5089-9884)
- Kayleigh Flies
- Elke De Bruyn (ORCID: https://orcid.org/0000-0003-2014-1540)
Institutions
- University of Antwerp (BE)
- Ghent University Hospital (BE)
- Ghent University (BE)
- VIB-UGent Center for Inflammation Research (BE)
- VIB-UGent Center for Medical Biotechnology (BE)
Publication Details
- Journal
- EMBO Reports
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1038/s44319-025-00441-5
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Union for International Cancer Control
- Fonds Wetenschappelijk Onderzoek
- Universiteit Gent
- Stichting Tegen Kanker
- Fondation contre le Cancer
- Bijzonder Onderzoeksfonds UGent